UroGen Pharma submits NDA to FDA for UGN-102 for low-grade intermediate-risk NMIBC

UroGen Pharma Ltd.

Completed NDA submission for UGN-102 to the U.S. FDA.
UGN-102 is intended for low-grade intermediate-risk non-muscle invasive bladder cancer treatment.
Regulatory submission marks a key milestone toward potential approval.

item 8.01

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-24-200993

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.